Prospective Randomized Multicenter Study in First-Line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas.

Trial Profile

Prospective Randomized Multicenter Study in First-Line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms MAINTAIN
  • Most Recent Events

    • 11 Jan 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2022.
    • 11 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2017 Initial results (n=612) comparing four versus two years of Rituximab maintenance following Bendamustine plus Rituximab (B-R) in first-line follicular lymphoma patients, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top